Cargando…

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark, Zhou, Xin, Zhao, Gexin, Chen, Hong, Li, Xinmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216110/ https://www.ncbi.nlm.nih.gov/pubmed/34164344 http://dx.doi.org/10.3389/fonc.2021.683419

Ejemplares similares

Editorial: Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology
por: Buzdin, Anton, et al.
Publicado: (2021)

Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology
por: Wang, Ye, et al.
Publicado: (2020)

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
por: Lai, Jiun-I, et al.
Publicado: (2020)

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021)

Spatial transcriptomics: Technologies, applications and experimental considerations
por: Wang, Ye, et al.
Publicado: (2023)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
por: Yang, Fan, et al.
Publicado: (2023)

Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014)

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
por: Allegretti, Matteo, et al.
Publicado: (2018)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019
por: Chu, Xuetong, et al.
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
por: Vaddepally, Raju K., et al.
Publicado: (2020)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis
por: Huang, Ya-fang, et al.
Publicado: (2020)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
por: Omae, Kenji, et al.
Publicado: (2019)

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
por: Hu, Jun Jacob, et al.
Publicado: (2020)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma
por: Ponzini, Francesca M, et al.
Publicado: (2023)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iphcputim7stq0qea8qqktejtf